Skip to main content

Table 1 Clinical characteristics of 537 RCC patients included in present study from TCGA database

From: The effect of a novel glycolysis-related gene signature on progression, prognosis and immune microenvironment of renal cell carcinoma

Variables Number (percentage)
Vital status
 Alive 367 (68.3%)
 Dead 170 (31.7%)
Age
 <65 336 (62.6%)
  ≥ 65 201 (37.4%)
Gender
 Male 346 (64.4%)
 Female 191 (35.6%)
Tumor Grade
 G1 14 (2.6%)
 G2 230 (42.8%)
 G3 207 (38.5%)
 G4 78 (14.5%)
 Gx 5 (1.0%)
 Unknow 3 (0.6%)
Clinical Stage
 Stage I 269 (50.1%)
 Stage II 57 (10.6%)
 Stage III 125 (23.3%)
 Stage IV 83 (15.4%)
 Unknow 3 (0.6%)
T stage
 T1 275 (51.2%)
 T2 69 (12.8%)
 T3 182 (33.9%)
 T4 11 (2.1%)
M stage
 M0 426 (79.3%)
 M1 79 (14.7%)
 Mx 30 (5.6%)
 Unknow 2 (0.4%)
N stage
 N0 240 (44.7%)
 N1 17 (3.2%)
 Nx 280 (52.1%)
Survival time (day) (170 dead samples)
  ≤ 365 52 (30.6%)
 365<ST ≤ 730 33 (19.4%)
 730<ST ≤ 1095 28 (16.5%)
  ≥ 1095 57 (33.5%)
Follow up (day) (367 alive samples)
  ≤ 365 66 (18.0%)
 365<FT ≤ 730 59 (16.1%)
 730<FT ≤ 1095 33 (9%)
  ≥ 1095 209 (56.9%)
  1. ST survival time, FT follow up time